SANUWAVE Health, Inc.
NASDAQ:SNWVMedical - Devices
+$0.18 today
- Market cap
- $51.01M
- Beta
- 1.34
- P/E (TTM)
- 5.0
- EPS (TTM)
- $1.87
Volume 0.04M
Average 0.11M
SNWV Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
SANUWAVE Health, Inc.NASDAQ: SNWV
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $975K a year earlier. Trailing-twelve-month stock-based compensation was -$2.38M.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 4.6 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$595.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.51M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How SNWV compares with its peers on the latest reported figures
- SNWV's LTM Mar 2026 stock-based compensation of $2.38M is the 10th largest of the 11 companies compared; the peer median is $9.25M.
- Its year-over-year change of -344.3% is the lowest of 11, against a peer median of -2.2%.
- Stock-based compensation amounts to 5.4% of revenue for SNWV, versus a peer median of 17.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.09M | -33.3% | -16.9% | 13.7% | |
| LTM Mar 2026 | $11.67M | -30.6% | +0.2% | 14.7% | |
| LTM Mar 2026 | $10.59M | +14.3% | +5.6% | 26.0% | |
| LTM Mar 2026 | $9.88M | -14.0% | +11.0% | 17.1% | |
| LTM Mar 2026 | $9.79M | +79.2% | +10.3% | 6.8% | |
| LTM Mar 2026 | $8.72M | +217.8% | — | 90.9% | |
| LTM Mar 2026 | $7.82M | +9.7% | -13.3% | 2.2% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| LTM Dec 2025 | $4.19M | -42.3% | -39.2% | 32.2% | |
| LTM Mar 2026 | $2.38M | -344.3% | — | 5.4% | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding SNWV) | $9.25M | -2.2% | +0.2% | 17.1% | |
Competitors are the stored peer set for SNWV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.26M) | (10.29M) | (25.81M) | (31.37M) | 11.81M |
| Depreciation & Amortization | 1.24M | 952K | 1.03M | 1.15M | 1.28M |
| Deferred Income Tax | 28K | 2K | 4K | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 1.51M | 0 |
| Change in Working Capital | 9.93M | (1.12M) | (3.61M) | (2.9M) | (4.01M) |
| Accounts Receivables | (395K) | (1.75M) | (53K) | (486K) | (2.3M) |
| Inventory | 1.69M | (72K) | (2.8M) | (1.2M) | (2.28M) |
| Accounts Payables | 3.18M | (2.55M) | 1.55M | (1.42M) | (521K) |
| Other Working Capital | 5.46M | 3.25M | (2.3M) | 203K | 1.09M |
| Other Non-Cash Items | 9.66M | (6.71M) | 23.84M | 34.07M | (5.21M) |
| Operating Cash Flow | (6.41M) | (17.17M) | (4.54M) | 2.46M | 3.88M |
| Capital Expenditures | (529K) | 1.02M | 0 | (490K) | (1.94M) |
| Acquisitions (Net) | 0 | 332K | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (1.02M) | 21K | 0 | 5.38M |
| Investing Cash Flow | (529K) | 332K | 21K | (490K) | 3.43M |
| Debt Repayment | 3.38M | 16.59M | 5.85M | (2.46M) | (6.14M) |
| Common Stock Issued | 0 | 100K | 0 | 10.3M | 556K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.74M | 695K | (639K) | (1.49M) | 0 |
| Financing Cash Flow | 5.12M | 17.38M | 5.21M | 6.35M | (5.59M) |
| Effect of Forex Changes | (1K) | (13K) | (50K) | 121K | 0 |
| Net Change in Cash | (1.82M) | 534K | 644K | 8.44M | 1.72M |
| Free Cash Flow | (6.94M) | (16.15M) | (4.54M) | 1.97M | 1.93M |
SANUWAVE Health, Inc.
NASDAQ:SNWV
Intrinsic Alpha fair value
Locked
Current Price
$5.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.